Zobrazeno 1 - 10 of 17 pro vyhledávání: '"Juhi Moon"'
2
Unreported alcohol use was common but did not impact hepatitis C cure in HIV‐infected persons who use drugs
Autor: Kayla Herne, Risha Irvin, Stephanie Katz, Kathleen M. Ward, Juhi Moon, Oluwaseun Falade-Nwulia, David L. Thomas, Geetanjali Chander, Lilian Arteaga, Shruti H. Mehta, Mark S. Sulkowski, Sean Manogue, Taryn Haselhuhn, Sherilyn Brinkley, Catherine G. Sutcliffe
Publikováno v: J Viral Hepat
BACKGROUND: We investigated the prevalence and impact of heavy alcohol use on the hepatitis C virus (HCV) care continuum among HIV/HCV co-infected persons who use drugs. METHODS: In the CHAMPS study, 144 HIV/HCV co-infected persons were randomized to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9e4d63ffc1238ca0d4946eb6b82a9da
https://doi.org/10.1111/jvh.13251
Zobrazit plný text záznamu
3
Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study
Autor: Anna S. Lok, Juhi Moon, Kenneth E. Sherman, Mandana Khalili, Dawn Fishbein, K. Rajender Reddy, Giuseppe Morelli, Joy Peter, David R. Nelson, Brian Pearlman, Larry Michael, Michael W. Fried, Jodi B. Segal, Mark S. Sulkowski
Publikováno v: Clinical Gastroenterology and Hepatology. 21:546-548.e4
Multiple real-world studies have confirmed the safety and efficacy of hepatitis C (HCV) direct-acting antivirals (DAAs); however, few studies have provided data on long-term outcomes of patients without cirrhosis after achieving sustained virologic r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9073140f104bfa7a7480aeefe5b53da6
https://doi.org/10.1016/j.cgh.2022.01.059
Zobrazit plný text záznamu
4
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
Autor: Gail V. Matthews, Sanjay Bhagani, Marc Van der Valk, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya L. Applegate, Jason Grebely, Phillipa Marks, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore, Marc van der Valk, Greg Dore, Pip Marks, Gail Matthews, Tanya Applegate, Jordan Feld, Jürgen Rockstroh, Sophia Amjad, Elise Tu, Mahshid Tamaddoni, Maria Christine Thurnheer, Yvonne Gilleece, Chris Fraser, Alberto Moriggia, Thomas Lutz, Juhi Moon, Phillip Read, Arthur Y. Kim, Andrew Ustianowski, Christiane Cordes, Joe Sasadeusz, Mark Hull, Dominique Braun
Publikováno v: Matthews, Gail V; Bhagani, Sanjay; Van der Valk, Marc; Rockstroh, Juergen; Feld, Jordan J; Rauch, Andri; Thurnheer, Christine; Bruneau, Julie; Kim, Arthur; Hellard, Margaret; Shaw, David; Gane, Ed; Nelson, Mark; Ingiliz, Patrick; Applegate, Tanya L; Grebely, Jason; Marks, Phillipa; Martinello, Marianne; Petoumenos, Kathy; Dore, Gregory J; ... (2021). Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of hepatology, 75(4), pp. 829-839. Elsevier 10.1016/j.jhep.2021.04.056
J Hepatol
Journal of hepatology, 75(4), 829-839. Elsevier
Background & Aims Shortened duration therapy for acute and recent HCV infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens; however, large randomised studies are lacking. Method
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56cb0f6e8b73a263af7310a4cfd284e8
https://boris.unibe.ch/156581/1/1-s2.0-S0168827821003366-main.pdf
Zobrazit plný text záznamu
6
High hepatitis C cure rates among black and nonblack human immunodeficiency virus–infected adults in an urban center
Autor: Catherine G. Sutcliffe, Jeanne C. Keruly, Jennifer Katzianer, Mark S. Sulkowski, David L. Thomas, Tanyaporn Wansom, Jillian Marks, Richard D. Moore, Juhi Moon, Geetanjali Chander, Shruti H. Mehta, Oluwaseun Falade-Nwulia, Amy Nathanson
Publikováno v: Hepatology. 66:1402-1412
Background Hepatitis C virus (HCV) cure rates have been similar in patients with and without HIV co-infection; however, in the ION-4 study, black patients treated with ledipasvir/sofosbuvir were significantly less likely to achieve cure (90%) compare
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::602306fe1cef34f774900567fff0a839
https://doi.org/10.1002/hep.29308
Zobrazit plný text záznamu
7
Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum
Autor: Richard D. Moore, David L. Thomas, Jeanne C. Keruly, Oluwaseun Falade-Nwulia, Mark S. Sulkowski, Geetanjali Chander, Shruti H. Mehta, Juhi Moon, Catherine G. Sutcliffe, Jennifer Katzianer
Publikováno v: Open Forum Infectious Diseases
Background Bolstered by the high efficacy of hepatitis C virus (HCV) treatment, the World Health Organization has called for HCV elimination by 2030. People with HIV (PWH) have been identified as a population in which elimination should be prioritize
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0cf307cf3e249c9da843d97c5d8d8d1
https://pubmed.ncbi.nlm.nih.gov/31667200
Zobrazit plný text záznamu
8
A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study
Autor: Catherine G. Sutcliffe, Stephanie Katz, Lilian Arteaga, Mark S. Sulkowski, Carl A. Latkin, Robert K. Brooner, Kathleen M Ward, Kayla Herne, Shruti H. Mehta, Juhi Moon, Sherilyn Brinkley, Oluwaseun Falade-Nwulia, Taryn Haselhuhn
Publikováno v: Open Forum Infectious Diseases
Background Despite access to direct-acting antivirals, barriers to a hepatitis C virus (HCV) cure persist, especially among persons living with human immunodeficiency virus (HIV) (PLWH) who use drugs. Interventions such as peer mentors or cash incent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83df7246cf9618726e28b274634f7f03
https://doi.org/10.1093/ofid/ofz166
Zobrazit plný text záznamu
9
Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease
Autor: Diana M. Brainard, Juhi Moon, John G. McHutchison, Mark S. Sulkowski, Fangqiu Zhang, Robert H. Hyland, Sophie Lanzkron
Publikováno v: Clinical Infectious Diseases. 65:864-866
Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3cff0f4bd2a364a25fa087824606d0b
https://doi.org/10.1093/cid/cix441
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje